Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?

OncoImmunology

Volumn 1, Issue 6, 2012, Pages 959-961

  Lindorfer, Margaret A ^a   Wiestner, Adrian ^b   Zent, Clive S ^c   Taylor, Ronald P ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c MAYO CLINIC   (United States)

Author keywords

CD20 mAbs; Immunomonitoring; Therapeutic antibodies; Therapeutic trials; Trogocytosis

Indexed keywords

OFATUMUMAB; RITUXIMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG TARGETING; HUMAN; IMMUNE EFFECTOR FUNCTION; IMMUNE RESPONSE; MACROPHAGE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; TROGOCYTOSIS;

EID: 84880983195     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.20368     Document Type: Article

References (10)

1. Beurskens FJ, Lindorfer MA, Farooqui M, Beum PV, Engelberts P, Mackus WJM, et al. Exhaustion of cyto-toxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients. J Immunol 2012; 188:3532-41; PMID:22368276; http://dx.doi.org/10.4049/jimmunol.1103693.
2. Golay J, Introna M. Mechanism of action of therapeutic monoclonal antibodies: Promises and pitfalls of in vitro and in vivo assays. Arch Biochem Biophys 2012; PMID:22387378; http://dx.doi.org/10.1016/j.abb.2012.02.011.
3. Coiffier B, Lepretre S, Pedersen LM, Gadeberg O, Fredriksen H, van Oers MHJ, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 2008; 111:1094-100; PMID:18003886; http:// dx.doi.org/10.1182/blood-2007-09-111781.
4. Tedder T F, Baras A, Xiu Y. Fcγ receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity. Springer Seminars in Immunopathology 2006; 28:351-64; http://dx.doi.org/10.1007/s00281-006-0057-9.
5. de Haij S, Jansen JHM, Boross P, Beurskens FJ, Bakema JE, Bos DL, et al. In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. Cancer Res 2010; 70:3209-17; PMID:20354182; http://dx.doi.org/10.1158/0008-5472.CAN-09-4109.
6. Wilson NS, Yang B, Yang A, Loeser S, Marsters S, Lawrence D, et al. An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell 2011; 19:101-13; PMID:21251615; http://dx.doi.org/10.1016/j.ccr.2010.11.012.
7. Kennedy AD, Beum PV, Solga MD, DiLillo DJ, Lindorfer MA, Hess CE, et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 2004; 172:3280-8; PMID:14978136; http://dx.doi.org/10.1016/j.jim.2004.08.004.
8. Williams ME, Densmore JJ, Pawluczkowycz AW, Beum PV, Kennedy AD, Lindorfer MA, et al. Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J Immunol 2006; 177:7435-43; PMID:17082663; http://dx.doi.org/http://www.jimmunol.org/content/177/10/7435.full.html.
9. Zent CS, LaBlant BR, Link BKCTG, Shanafelt TD, Bowen DA, Kay NE, et al. Pentostatin, alemtu-zumab and low dose rituximab is effective therapy for relapsed/refractory chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL). Blood (ASH Annual Meeting Abstracts) 2011; 118; Abstract 1790;
10. Schreiber AD, Frank MM. Role of antibody and complement in the immune clearance and destruction of erythrocytes. I. In vivo effects of IgG and IgM complement-fixing sites. J Clin Invest 1972; 51:575-82; PMID:4536807; http://dx.doi.org/10.1172/JCI106846.